Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The immunosuppressants cyclosporin A (CsA) and FK506 appear to block T-cell function by inhibiting the calcium-regulated phosphatase
calcineurin
. While multiple distinct intracellular receptors for these drugs (cyclophilins and FKBPs, collectively immunophilins) have been characterized, the functionally active ones have not been discerned. We found that overexpression of cyclophilin A or B or FKBP12 increased T-cell sensitivity to CsA or FK506, respectively, demonstrating that they are able to mediate the inhibitory effects of their respective immunosuppressants in vivo. In contrast,
cyclophilin C
, FKBP13, and FKBP25 had no effect. Direct comparison of the Ki of each drug-immunophilin complex for
calcineurin
in vitro revealed that although
calcineurin
binding was clearly necessary, it was not sufficient to explain the in vivo activity of the immunophilin. Subcellular localization was shown also to play a role, since gene deletions of cyclophilins B and C which changed their intracellular locations altered their activities significantly. Cyclophilin B has been shown previously to be located within calcium-containing intracellular vesicles; its ability to mediate CsA inhibition implies that certain components of the signal transduction machinery are also spatially restricted within the cell.
...
PMID:Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. 768 44
This study identifies a 100-residue domain within the rabbit skeletal muscle regulatory subunit (PP1G) that binds both type-1
protein phosphatase
(PP1C) and glycogen. An N-terminal portion of PP1G was cloned by RT-PCR, and different sized fragments were expressed in bacteria as glutathione S-transferase (GST) fusion proteins. A GST-PP1G fusion containing residues 51-240 bound both
PPIC
and glycogen, whereas GST alone or fusions containing residues 51-140 or 241-360 bound neither PP1C nor glycogen. The
PPIC
in whole cell lysates or partially purified PP1C from skeletal muscle, or a complex of PP1C-MCLR-biotin, all bound more effectively than Mn(2+)-activated, recombinant PP1C purified from bacteria. Binding was enhanced by increasing the ionic strength and was disrupted by ethylene glycol, consistent with hydrophobic interactions being critical for stable association. Phosphorylation of the GST-PP1G fusion by cAMP-dependent protein kinase prevented completely association of PP1C. This domain of PP1G, from residues 141-240, contains two sequence motifs of hydrophobic residues: Gx8FEKx10W and DxFxFxIxL, that are conserved among the known glycogen-binding PP1 regulatory subunits. These segments are predicted to form an alpha helix and a beta sheet, and we propose that they are the sites for association with PP1C and glycogen, respectively.
...
PMID:Protein phosphatase type-1 and glycogen bind to a domain in the skeletal muscle regulatory subunit containing conserved hydrophobic sequence motif. 890 29
Experimental cerebral ischemia has been reportedly alleviated by the immunosuppressive agent cyclosporin A (CsA). Cyclophilin C-associated protein (CyCAP) was proposed to be an endogenous equivalent of CsA; CsA- and CyCAP-targeting protein
cyclophilin C
have attracted extensive attention regarding their ischemia-alleviating mechanisms. In this study we have introduced the specific CyCAP antibody for evaluating its distribution in the rat ischemic brain after middle cerebral artery occlusion. During the recovery of cerebral ischemia in rats, CyCAP was highly expressed in the activated microglia/macrophages in the ischemic lesion. However, it remains unknown what roles CyCAP plays in the activation of macrophage phagocytosis. Thus, we studied CyCAP function using a RAW264.7 macrophage cell line. When we expressed CyCAP-GFP and
cyclophilin C
-FLAG in RAW264.7 cells, we found that CyCAP and
cyclophilin C
make a complex, which is competitively inhibited by CsA. Consistently, in immunoprecipitates by anti-
calcineurin
antibody,
cyclophilin C
and CyCAP were detected, and CyCAP pulled down NFATc1, suggesting that both CyCAP and
cyclophilin C
form a complex with
calcineurin
and NFATc1. When CyCAP was adenovirally overexpressed in RAW cells, NFAT staining increased over the nucleus. Furthermore,
calcineurin
and IL-2 were increased with time. Thus, CyCAP appears to control macrophage functions by activating NFAT and the resultant IL-2 production. With a
protein phosphatase
inhibitor PhoSTOP, NFAT was localized more to the cytoplasm, and phagocytosis was decreased strikingly. Thus, we suggest that in a CyCAP-
cyclophilin C
pathway for macrophage activation,
calcineurin
phosphatase activity is essential for the phagocytosis activity via dephosphorylation of NFATc1.
...
PMID:Cyclophilin C-associated protein regulation of phagocytic functions via NFAT activation in macrophages. 2143 37